Biogen Pharmachem Industries Reports Strong Quarterly Results Amid Long-Term Challenges
Biogen Pharmachem Industries has recently adjusted its evaluation due to strong quarterly financial performance, with key metrics reaching a peak. However, the company faces longer-term challenges, including a low Return on Equity and debt management concerns, alongside a significant decline in stock performance over the past year.
Biogen Pharmachem Industries has recently undergone an adjustment in its evaluation, reflecting notable shifts in its financial metrics and market position. The company reported a very positive financial performance for the quarter ending June 2025, with key indicators such as PBDIT, PBT less OI, and PAT all reaching a peak of Rs 1.34 crore. This performance has contributed to a revision in its score, highlighting the company's recent financial achievements.Despite these positive quarterly results, the stock has faced challenges over the longer term. The average Return on Equity (ROE) stands at 1.84%, indicating some weaknesses in fundamental strength. Additionally, the company's ability to manage its debt is under scrutiny, as evidenced by a low EBIT to Interest ratio of 1.19.
In terms of market performance, Biogen Pharmachem Industries has experienced a decline of 31.29% over the past year, contrasting sharply with the broader market's modest gains. The stock's current price is 1.01, with a 52-week high of 1.54 and a low of 0.75, suggesting a volatile trading environment.
Overall, the recent evaluation adjustment reflects a complex interplay of strong quarterly results against a backdrop of longer-term challenges.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
